COMMUNIQUÉS West-GlobeNewswire

Sonablate announces first patient enrolled in HIFIVE U.S. clinical trial for ablation of incompetent veins

28/10/2024 - 19:36

HIFIVE is a single arm, single institution, Phase I trial to assess the safety and performance of Sonablate high-intensity focused ultrasound for treating incompetent veins including vascular malformations CHARLOTTE, N. [...]

Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months

28/10/2024 - 19:00

Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months —Late-breaking 12-month [...]

Après six mois, le DynamX Bioadaptor d’Elixir Medical fait preuve d’une amélioration importante en comparaison des stents à élution médicamenteuse (DES), chez les patients atteints de syndrome coronarien aigu et de lésions complexes

28/10/2024 - 19:00

Après six mois, le DynamX Bioadaptor d’Elixir Medical fait preuve d’une amélioration importante en comparaison des stents à élution médicamenteuse (DES), chez les patients atteints de syndrome coronarien aigu et de [...]

BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

28/10/2024 - 18:58

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and [...]

Oxford Treatment Center Leads the Way in Delivering Veteran Ready Care with New PsychArmor Certification

28/10/2024 - 17:51

ETTA, Miss., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oxford Treatment Center has joined a small group of addiction treatment providers across the nation that have achieved Veteran Ready Certification from PsychArmor, a [...]

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

28/10/2024 - 17:47

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY ADDING [...]

AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

28/10/2024 - 17:47

COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET EUROPÉEN COUVRANT JUSQU'EN 2040 LE MASITINIB DANS LE TRAITEMENT DE LA DREPANOCYTOSE CETTE DÉCISION RENFORCE LA PROPRIÉTÉ INTELLECTUELLE DU [...]

ONWARD® Medical Publishes Closing of Bookbuild Offering

28/10/2024 - 17:45

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Oct. 28, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]

IHA selects Cozeva as their sole analytics partner for all performance measurement programs

28/10/2024 - 17:00

Expanded partnership between IHA and Cozeva will implement redesign of flagship AMP program and drive healthcare quality and equity performance forward in California OAKLAND, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- [...]

BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests

28/10/2024 - 16:26

28 October 2024 Announcement no. 19 BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests COPENHAGEN, DENMARK and BOSTON, MA, USA, October 28, 2024 (GLOBE NEWSWIRE) – [...]

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity

28/10/2024 - 15:00

BERKELEY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- HOPO Therapeutics, Inc. announced today that it has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development [...]

Medicovestor, Inc. Announces Issuance/Approval of 3 Patents by the USPTO

28/10/2024 - 15:00

NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Medicovestor, Inc., a leading innovator in biotechnology, today announced the issuance of two new patents and the approval of an additional patent by the U.S. Patent and [...]

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

28/10/2024 - 14:31

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of [...]

VIVUS Shares Significant Regulatory Update on QSYMIA®

28/10/2024 - 14:30

- Postmarketing requirement fulfilled based on data demonstrating QYSMIA® reduces blood pressure - CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and Drug Administration has [...]

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

28/10/2024 - 14:25

The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN [...]

Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children’s Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia

28/10/2024 - 14:00

Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company [...]

Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024

28/10/2024 - 14:00

GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer [...]

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

28/10/2024 - 14:00

SUNNYVALE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today [...]

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

28/10/2024 - 13:30

MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of [...]